| pioglitazone / Generic mfg. |
NCT01280695: A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients |
|
|
| Completed | 2a | 129 | US | Placebo, MSDC-0602 100 mg, MSDC-0602 250 mg, Pioglitazone | Metabolic Solutions Development Company | Diabetes Mellitus, Type 2 | 06/11 | 06/11 | | |
NCT01230749: A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 2 | 89 | US | JNJ-41443532, Pioglitazone 30 mg, Placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Diabetes Mellitus, Type 2 | 06/11 | 06/11 | | |
| Completed | 2 | 51 | Europe | Vildagliptin, Galvus, Pioglitazone, Actos, Life-Style Modification | Marcus Saemann | Impaired Glucose Tolerance, Kidney Transplantation | 11/11 | 11/11 | | |
|
|
NCT02195791: Neuroprotection of Pioglitazone in Acute Ischemic Stroke |
|
|
| Terminated | 2 | 4 | RoW | Pioglitazone, Placebo | Taipei Medical University Shuang Ho Hospital | Stroke | 08/16 | 08/16 | | |
